Need more? Try out  Advanced Search (20+ criteria)»

logo

Last Update

This profile was last updated on 7/21/2017 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong Franklin Pass?

Franklin Pass

Member, Faculty

Albert Einstein College of Medicine

HQ Phone:  (718) 430-2000

Email: f***@***.edu

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Albert Einstein College of Medicine

1300 Morris Park Avenue Belfer Building, Room 1008

The Bronx, New York,10461

United States

Company Description

About Albert Einstein College of Medicine ?Albert Einstein College of Medicine is one of the nation's premier centers for research, medical education and clinical investigation. During the 2015-2016 academic year, Einstein is home to 731 M.D. students, 193 Ph....more

Background Information

Employment History

Dermatologist

Oregon Health & Science University


Director

American Academy of Dermatology


Chief Executive Officer

Medi-Ject Corporation


Affiliations

Molecular Genetics , Inc.

Founder


Bioseeds International , Ltd.

Founder


Industrial Biotechnology Association

Cofounder


Education

University of Minnesota Medical School


M.D.


medical degree

University of Minnesota , School of Medicine


Web References(25 Total References)


A Blood Test For Women With Breast Cancer

www.martelldiagnostic.com [cached]

Franklin Pass, M.D., Chairman and CEO - Frank graduated from the University of Minnesota and University of Minnesota Medical School and then trained at Oregon Health Sciences University as a dermatologist.
Following a dermatology residency and military service, he joined the faculty of Albert Einstein College of Medicine. At Einstein, he spent six years in an immunochemistry and molecular virology laboratory. He organized and led the residency training program in dermatology and collaborated in early human papilloma virus research. He returned to the faculty of the University of Minnesota Medical School in 1973 to continue his HPV research, which ultimately resulted in the formation of Molecular Genetics, Inc. in 1979. Dr. Pass formed MOGEN, a Dutch plant biotechnology research company that today is part of Syngenta. Dr. Pass left Molecular Genetics in 1987 to found Bioseeds International, Ltd. Bioseeds was purchased by Calgene in 1990. Dr. Pass then became CEO of Medi-Ject Corporation, assembled a cadre of engineers and greatly advanced the mechanics of needle-free drug delivery. Medi-Ject was merged with a Swiss drug delivery company in 2000 and today is Antares Pharma, Inc. In all, Dr. Pass has been a co-founder and CEO of six companies in the field of agricultural biotechnology, drug delivery, pharmaceutical discovery and diagnostics, three of which became public corporations with eventual shareholder value in excess of $4.0 billion. He has been a co-founder and leader of three professional associations and served as a director of several civic arts organizations. His academic and industry contributions in the field of HPV helped to delineate the role of HPV in human cancer and in the design of papilloma virus vaccines, and he supported the fundamental development of genetically modified corn. Dr. Pass has published over forty scientific papers. They have been meeting regularly and advising Dr. Pass. Doug worked with Dr. Pass at two early stage biotechnology ventures dating back to 1980. Richard is a molecular biologist, who began his career as a postdoc in a University of Minnesota lab with Dr. Pass.


A Blood Test For Women With Breast Cancer

www.martelldiagnostic.com [cached]

Franklin Pass, M.D., Chairman and CEO - Frank graduated from the University of Minnesota and University of Minnesota Medical School and then trained at Oregon Health Sciences University as a dermatologist.
Following a dermatology residency and military service, he joined the faculty of Albert Einstein College of Medicine. At Einstein, he spent six years in an immunochemistry and molecular virology laboratory. He organized and led the residency training program in dermatology and collaborated in early human papilloma virus research. He returned to the faculty of the University of Minnesota Medical School in 1973 to continue his HPV research, which ultimately resulted in the formation of Molecular Genetics, Inc. in 1979. Dr. Pass formed MOGEN, a Dutch plant biotechnology research company that today is part of Syngenta. Dr. Pass left Molecular Genetics in 1987 to found Bioseeds International, Ltd. Bioseeds was purchased by Calgene in 1990. Dr. Pass then became CEO of Medi-Ject Corporation, assembled a cadre of engineers and greatly advanced the mechanics of needle-free drug delivery. Medi-Ject was merged with a Swiss drug delivery company in 2000 and today is Antares Pharma, Inc. In all, Dr. Pass has been a co-founder and CEO of six companies in the field of agricultural biotechnology, drug delivery, pharmaceutical discovery and diagnostics, three of which became public corporations with eventual shareholder value in excess of $4.0 billion. He has been a co-founder and leader of three professional associations and served as a director of several civic arts organizations. His academic and industry contributions in the field of HPV helped to delineate the role of HPV in human cancer and in the design of papilloma virus vaccines, and he supported the fundamental development of genetically modified corn. Dr. Pass has published over forty scientific papers. Doug worked with Dr. Pass at two early stage biotechnology ventures dating back to 1980. Richard is a molecular biologist, who began his career as a postdoc in a University of Minnesota lab with Dr. Pass.


PepTx

www.peptx.com [cached]

Franklin Pass, M.D., Director
Dr. Pass is a physician, biomedical entrepreneur and investment banker. From 2001 to the present, he has led the Life Sciences securities practice of Cherry Tree, a Minnesota investment banking firm. From 1992 to 2001, Dr. Pass was the CEO of Antares Pharma, Inc. and its predecessor, Medi-Ject Corporation, a manufacturer of device-based drug delivery systems. Dr. Pass spent the prior fifteen years organizing and leading three agricultural biotechnology companies, two in the U.S. and one in the Netherlands. Prior to that time, he was employed by Albert Einstein College of Medicine and the University of Minnesota as a professor and academic scientist in the field of dermatology and molecular virology. Dr. Pass received his undergraduate and medical education at the University of Minnesota.


SEC EDGAR Submission 0001193125-05-061028

www.sec.gov [cached]

Continuing as directors for the Company but not subject to re-election were directors Frank Massino, George Fellows, Kevin McCarthy, Anthony Williams and Dr. Franklin Pass.Franklin PassDirectorDr. Franklin Pass was appointed a director in February 2002.Since March 2001 he has been Vice Chairman of Antares Pharma, Inc., which develops and markets pharmaceutical delivery systems, and is Managing Director at Cherry Tree Securities, a Minnesota-based investment banking group which provided consulting services to the Company from January 2002 to June 2002.Since 2003 Dr. Pass has also served as a Director of Peptx, Inc., a privately held venture stage drug development company.Previously, Dr. Pass was Chairman and CEO of Antares Pharma, Inc., BioSeeds International, Ltd., and Molecular Genetics, Inc. (MGI Pharma, Inc.), which he co-founded.He served as CEO of Medi-ject Corp. from 1993 to 2001.He has served as Director of the American Academy of Dermatology, Director of Dermatology at the Albert Einstein College of Medicine, and Clinical Professor at the University of Minnesota, Department of Dermatology.He received his medical degree from the University of Minnesota, School of Medicine. The Board of Directors has determined that Dr. Franklin Pass, a member of the Audit Committee, qualifies as an "audit committee financial expert," and is "independent," as defined in applicable SEC rules.


www.sec.gov

Franklin PassDirectorFranklin Pass was appointed a Director in February 2002 and was re-elected by shareholder at the Annual General Meeting in May 2002.Since March 2001, he has been Vice Chairman of Antares Pharma, Inc. (formerly known as Mediject Corporation), which develops and markets pharmaceutical delivery systems, and is a Managing Director of Cherry Tree Development LLC, a Minnesota-based investment banking group.From 1993 to 2000, Dr. Pass was Chairman and CEO of Mediject Corporation.He has served as Director of the American Academy of Dermatology, Director of Dermatology at the Albert Einstein College of Medicine, and Clinical Professor at the University of Minnesota, Department of Dermatology.He received his medical degree from the University of Minnesota, School of Medicine. The Compensation Committee currently consists of Dr. Pass (Chairman) and Messrs.During 2003, the Compensation Committee consisted initially of Dr. Pass (Chairman).Dr. Pass replaced Mr. Williams as Chairman in 2004.The Audit Committee currently consists of Mr. Fellows (Chairman), Dr. Pass and Dr. Thieme.During 2003, the Audit Committee consisted initially of Mr. Tobler (Chairman), Dr. Pass and Dr. Thieme.Williams and McCarthy, Mr. Tobler and Dr. Pass were replaced on the Committee by Messrs.Dr. Pass replaced Mr. McCarthy in October 2004.McCarthy and Pass.Dr. Pass is "independent" within the meaning of the listing standards of the Nasdaq Stock Market. The Nominating Committee was established in October 2003.The Nominating Committee currently consists of Messrs.Fellows (Chairman) and Williams and Dr. Pass.Mr. McCarthy stepped down in October 2004 in favor of Dr. Pass.The Board has determined that the following directors of the Company (constituting a majority of all directors) are "independent" within the meaning of the listing standards of the Nasdaq Stock Market: Mr. Fellows, Mr. Williams, Dr. Pass and Dr. Thieme. Franklin PassIncludes the following number of shares issuable upon exercise of options that are currently exercisable or will become exercisable within 60 days of September 30, 2004: Mr. Massino: 3,050,000; Dr. Thieme: 280,000; Mr. Tobler: 845,000; Mr. Slade: 185,000; Dr. Pass: 150,000;Mr.Includes the following number of shares issuable within 60 days from deferred compensation accounts maintained by certain executive officers and directors of the Company pursuant to deferred compensation arrangements entered into by such executive officers and directors with the Company effective January 1, 2004 pursuant to which ten percent of base salary (in the case of the executive officers) or quarterly director fees (in the case of non-employee directors) could be deferred and applied to Ordinary share equivalent units: Mr. Massino: 44,466; Mr. Tobler 8,501; Dr. Pass 15,766; Mr. Nichols 33,872; Mr. McCarthy 15,766; Mr. Fellows 15,766; Mr. Williams 15,766; and Mr. Holsworth: 25,787.Cherry Tree Development, LLC, an entity affiliated with board member Dr. Franklin Pass, was compensated a total of $36,000 for its services during 2003.


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory